Dnanexus, Inc.
Mountain View, CA Doing business as Dnanexus Inc.
- UEI
- D3WLJYBFS2M3
- CAGE
- 5KNP1
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1975 W El Camino Real #204, Mountain View, CA 94040, USA
- Website
- dnanexus.com
- Founded
- 2009
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Information Technology
- Software & Services
- IT Services
- Data Processing & Outsourced Services
- SIC code
- 73 Business Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| FY26 precisionfda public instance of gsrs o & m | Food and Drug Administration | $251,730 | |
| Dnanexus INC:1186901 [25-003391] | Assistant Secretary for Financial Resources | $20,204 | |
| Computing infrastructure providers, data processing, web hosting, and related services - access and utilize the research… | National Institute on Aging | $14,000 | |
| Adapt - advanced analysis for precision cancer therapy treatment and analysis plan (TAP) | Interior Business Center | $6,756,680 | |
| Precisionfda provides a fisma-authorized secure cloud-based data repository and analysis platform for reviewers,… | Food and Drug Administration | $6,697,396 |
About Dnanexus, Inc.
Dnanexus, Inc., headquartered in Mountain View, California, delivers cloud-based genomics data management, bioinformatics analysis platforms, and precision medicine research infrastructure to the National Institutes of Health, the Food and Drug Administration, and the National Cancer Institute as a for-profit prime contractor (100% of recent awards). The company operates exclusively in full-and-open competition with no SBA set-aside designations across its prime footprint, except for a single Total Small Business set-aside delivery order from the FDA in FY26.
Customer concentration is extreme and anchored to HHS. The FDA accounts for 19 awards and $66.1 million of the $82.1 million combined potential value across the 31-award footprint (81% of dollars), with the remaining $16 million spread across NIH, the National Cancer Institute, the National Human Genome Research Institute, the National Institute on Aging, and the National Heart Lung and Blood Institute. Across SCI-reportable service contracts (FY2022–FY2024), Dnanexus invoiced $9.6 million to the federal government — $3.6 million in FY2022, $4.8 million in FY2023, and $1.1 million in FY2024 — with FTE delivery declining from 6.0 FTEs in FY2023 to 1.8 FTEs in FY2024. Government-paid hourly rates on SCI prime contracts ranged from $229.81/hr at the 10th percentile to $570.23/hr at the 90th percentile, with a median of $311.49/hr.
Dnanexus operates almost exclusively as a prime contractor; it reports 1% sub-hours share across its SCI prime contracts and maintains no named major subcontractor relationships. The company's parent vehicle is a $26.8 million indefinite delivery contract (75F40119D10041) against which 15 task orders have been placed. Representative prime work includes a $15 million Other Transaction Agreement with the National Institutes of Health (awarded May 20, 2025, running through May 19, 2031) for the ADAPT (Advanced Analysis for Precision Cancer Therapy) Treatment and Analysis Platform, a $6.8 million delivery order from the FDA (September 26, 2024) for the PrecisionFDA platform providing a FISMA-authorized secure cloud-based data repository and analysis environment, and a $647,500 sole-source purchase order from the National Cancer Institute (September 9, 2024) for Platform as a Service cloud-based data analysis and management capabilities to support the Confluence Project.
The vendor's capability portfolio centers on FISMA-authorized cloud infrastructure, genomic data harmonization and analysis, bioinformatics software platforms, precision medicine research environments, and regulatory science collaboration tools. Work is performed at Dnanexus headquarters in Mountain View, California, and at customer sites including Rockville, Maryland and Silver Spring, Maryland for FDA work. Awards per year have averaged four to six annually over the past five years, with three awards reaching ultimate completion inside the next twenty-four months and carrying combined potential value of $919 thousand, indicating modest recompete exposure in the near term. The company registered in SAM.gov in 2009 and has maintained continuous federal engagement in genomics and precision medicine infrastructure since fiscal year 2021.
Quick answers
What is Dnanexus, Inc.'s UEI?
Dnanexus, Inc.'s Unique Entity ID (UEI) in SAM.gov is D3WLJYBFS2M3.
What is Dnanexus, Inc.'s CAGE code?
Dnanexus, Inc.'s CAGE code is 5KNP1.
What is Dnanexus, Inc.'s primary NAICS code?
Dnanexus, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Dnanexus, Inc. located?
Dnanexus, Inc.'s physical address in SAM.gov is 1975 W El Camino Real #204, Mountain View, CA 94040, USA.
Is Dnanexus, Inc. registered in SAM.gov?
Yes. Dnanexus, Inc.'s SAM.gov registration is active through August 30, 2027.
What is Dnanexus, Inc.'s most recent federal award?
Dnanexus, Inc.'s most recent federal contract award is FY26 precisionfda public instance of gsrs o & m (75F40126F19018), from Food and Drug Administration, on May 28, 2026.
On GovTribe
See Dnanexus, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors